LRFN5 and OLFM4 in Schizoaffective Disorder

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorElazığ Mental Health and Diseases Hospital

About this trial

Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging evidence suggests that Leucine-Rich Repeat and Fibronectin Type-III Domain-Containing Protein 5 (LRFN5) and olfactomedin-4 (OLFM4) may play roles in synaptic organization, neurodevelopment, and neuroinflammation. However, no prior study has investigated these biomarkers in SAD. This cross-sectional case-control study aims to compare peripheral serum levels of LRFN5 and OLFM4 in subjects diagnosed with SAD in remission and healthy control subjects. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in SAD.

Eligibility criteria

Qualifiers

Diagnosis of SAD according to DSM-5-TR

Acute manic episode

Medication-free for at least one month prior to admission

Age ≥ 18 years and <65 years

Disqualifiers

Alcohol/drug/substance use

Medication-free for at least one month

Age ≥ 18 years and < 65 years

Provided informed consent

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

120 Participants
are grouped into 2 trial groups